| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4003758 | American Journal of Ophthalmology | 2010 | 11 Pages |
Abstract
Bepotastine besilate ophthalmic solutions 1.0% and 1.5% both substantially decreased CAC-induced ocular itching for at least 8 hours after dosing. Reductions in conjunctival hyperemia after a CAC, although statistically significant for bepotastine besilate ophthalmic solutions 1.0% and 1.5% compared with placebo when assessed at 15 minutes after dosing, were modest.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Thomas T. Macejko, Mark T. Bergmann, Jon I. Williams, James A. Gow, Paul J. Gomes, Timothy R. McNamara, Mark B. Abelson, Bepotastine Besilate Ophthalmic Solutions Clinical Study Group Bepotastine Besilate Ophthalmic Solutions Clinical Study Group,